信達(da)生物制藥(yao)集團宣布：胰高血糖(tang)素(su)樣肽-1受(shou)體（glucagon-like peptide-1 receptor, GLP-1R）/胰高血糖(tang)素(su)受(shou)體（glucagon receptor, GCGR）雙重激動劑(ji)mazdutide (研(yan)發代號：IBI362)在中(zhong)國2型糖(tang)尿病受(shou)試(shi)(shi)者中(zhong)的(de)一(yi)項多(duo)中(zhong)心(xin)、隨機、度拉糖(tang)肽對照(zhao)的(de)III期臨床研(yan)究(jiu)（DREAMS-2）完(wan)成(cheng)首例受(shou)試(shi)(shi)者給藥(yao)。(醫藥(yao)健聞)